Back to search results
NCT07605052

A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body Weight

Active, Not Recruiting
PHASE1Ages 18–64InterventionalTreatment
Novo Nordisk A/S
~50 participants
Updated 2026-08-17 on ClinicalTrials.gov
What's tested:Cagrilintide BCagrilintide D

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
AUCss: area under the total cagrilintide concentration-time curve at steady state after 5th dosing of cagrilintide
Measured over From Pre-dose at Day 29 to Day 36
+1 more outcome measured

Conditions

Overweight
Obesity

Explore related trials

ObesityOverweight

Where it's being run

1 sites across 1 states
Arizona1

Study leadership

  • Clinical Transparency (dept. 2834) · STUDY_DIRECTOR · Novo Nordisk A/S

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 18-64 years (both inclusive) at the time of signing informed consent.
Male or female (sex assigned at birth).
Body mass index (BMI) between 27.0 and 34.9 kilogram per meter square (kg/m\^2) (both inclusive) at screening. Overweight should be due to excess adipose tissue, as judged by the investigator.
Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram (ECG), and clinical laboratory tests performed during the screening visit, as judged by the investigator.

Exclusion

Previous dosing of marketed or non-marketed amylin-agonists (a).
Any condition, unwillingness or inability which in the investigator's opinion might jeopardise the participant's safety or compliance with the protocol (a).

What this trial measures

  • AUCss: area under the total cagrilintide concentration-time curve at steady state after 5th dosing of cagrilintideFrom Pre-dose at Day 29 to Day 36

    Measured as hour\*nanomole per liter (h\*nmol/L).

  • Cmax,ss: maximum observed concentration of total cagrilintide at steady state after 5th dosing of cagrilintideFrom Pre-dose at Day 29 to Day 36

    Measured as nanomole per liter (nmol/L).